Glossary
|
Site Map
|
Contact Us
about us
product pipeline
technology
clinical trials
investors & news
careers
•
Management
•
Board of Directors
•
Collaborations
•
Brentuximab Vedotin
(SGN-35)
•
Lintuzumab (SGN-33)
•
Dacetuzumab (SGN-40)
•
SGN-70
•
SGN-75
•
Preclinical Programs
•
Scientific Publications
•
ADC Technology
•
SEA Technology
•
Scientific Publications
By Program:
•
Brentuximab Vedotin
(SGN-35)
•
Lintuzumab (SGN-33)
•
Dacetuzumab (SGN-40)
•
SGN-70
•
SGN-75
By Indication:
•
Hodgkin Lymphoma
•
Non-Hodgkin Lymphoma
•
Multiple Myeloma
•
Leukemia/MDS
•
Autoimmune
•
Solid Tumors
•
Press Releases
•
Stock Performance
•
SEC Filings
•
Webcasts & Events
•
Scientific Publications
•
Corporate Governance
•
Analyst Coverage
•
Financial Reports
•
Investor FAQ
•
Information Request
•
Benefits
•
Living in the Area
•
Job Opportunities
In the News
02/03/2010
Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
02/02/2010
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2009 Financial Results on February 9, 2010
Webcasts and Events
Event:
RBC Capital Markets Healthcare Conference
Date:
03/03/2010
Time:
12:00 PM
Event:
Fourth Quarter and Year 2009 Earnings Conference Call
Date:
02/09/2010
Time:
02:00 PM